Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer.

Journal Article (Journal Article)

Background/aim

We have previously found elevated levels of endoglin (CD105) in the prostate cancer (PC) tissue of men with poor prognosis, compared to men with indolent disease. Herein, we examined whether plasma levels of the soluble form of CD105 (sCD105) differ according to the PC grade at diagnosis.

Patients and methods

We measured sCD105 in 73 subjects with biopsy-confirmed PC at the Durham, North Carolina, Veteran Affairs Health System. The association between sCD105 and intermediate/high-grade PC risk [Gleason Group (GG) 2-5 vs. 1] was examined using regression models.

Results

Of 73 men, 27 had low-grade PC and 46 high-grade PC. Higher GG was linked to lower sCD105 (GG1: 6938 pg/ml, GG2-3: 6150 pg/ml, GG4-5: 5554 pg/ml; p=0.012). On multivariable analysis, lower sCD105 was associated with increased high-grade PC risk (ORper 1000 units =1.33, p=0.028).

Conclusion

Lower sCD105 levels were associated with intermediate and high-risk PC. Further investigation is warranted in a larger PC cohort.

Full Text

Duke Authors

Cited Authors

  • Vidal, AC; Duong, F; Howard, LE; Wiggins, E; Freedland, SJ; Bhowmick, NA; Gong, J

Published Date

  • March 2020

Published In

Volume / Issue

  • 40 / 3

Start / End Page

  • 1459 - 1462

PubMed ID

  • 32132043

Pubmed Central ID

  • PMC7768804

Electronic International Standard Serial Number (EISSN)

  • 1791-7530

International Standard Serial Number (ISSN)

  • 0250-7005

Digital Object Identifier (DOI)

  • 10.21873/anticanres.14088

Language

  • eng